Oxford Nanopore has revealed plans to list on London Stock Exchange in an initial public listing that could value the firm as highly as £4bn.
The biotech firm has achieved global recognition with its DNA sequencing devices used for identifying and tracking the spread of Covid-19 variants, while in the UK, the firm supplied the NHS with rapid tests. Oxford Nanopore represents almost half of new Cayman-based Woodford fund In its latest funding round, the company was valued at £2.4bn but the IPO could see the firm valued around £4bn, according to analysts at Jefferies. The estimate was based on the firm's 2023 revenue targets and in comparison to its closest listed rival, $6bn Pacific Biosciences. In the six months to Ju...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
